Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Articles
Articles
Discussing Costs with Your Patient Can Reduce Financial Toxicity
By
Chase Doyle
Economics & Value
,
Financial Toxicity
,
Value-Based Care
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
“Treating financial toxicity at the patient level is similar to treating a symptom like fatigue. You can try to prevent it, but to some degree, patients are going to experience it, and when they do, you need a plan,” says Yousuf Zafar, MD, MHS.
Read More
Chemotherapy Can Be Spared in Many Patients with Early Breast Cancer: Devil Is in the Details
By
Phoebe Starr
Breast Cancer
,
Chemotherapy
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read More
Precision Medicine and Immunotherapy Highlighted at ASCO 2018
By
Wayne Kuznar
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Interest in personalizing medicine in oncology is growing, so the American Society of Clinical Oncology (ASCO) titled its theme for the 2018 presidential address at the annual meeting, "Delivering Discoveries: Expanding the Reach of Precision Medicine."
Read More
New Clues to Mismatch Repair and PD-1/PD-L1 Status and Survival in Patients with Gastric or Esophageal Cancer
By
Charles Bankhead
Gastrointestinal Cancers
Web Exclusives
San Francisco, CA—Understanding the complex relationship between the PD-1 receptor, its ligand 1 (PD-L1), and mismatch repair deficiency (dMMR) status may help to improve treatment outcomes in patients with resectable gastric and esophageal cancer, according to a retrospective tissue-based analysis.
Read More
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
ASH 2017
,
Multiple Myeloma
,
Palliative Care
,
Hematologic Malignancies
,
ASH Highlights
Web Exclusives
Read More
Expanding Treatment Options for Patients with Advanced Cholangiocarcinoma
By
Wayne Kuznar
Cholangiocarcinoma
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—A greater understanding of the biology of cholangiocarcinoma, including differences between intrahepatic versus extrahepatic cholangiocarcinoma, is driving the development of new therapeutic options that have shown promising results in advanced stages of this difficult-to-treat cancer.
Read More
NCCN Panel Debates Cancer Care in Value-Based Healthcare Models
By
Wayne Kuznar
NCCN Annual Conference
,
Value in Oncology
Web Exclusives
Experts at this roundtable discussion addressed high patient costs, achieving greater value in oncology care, and the desire for access to comparative data.
Read More
What the Next Generation of Cancer Biomarkers May Involve
By
Sanjiv S. Agarwala, MD
ASCO 2018 Insights
Videos
Dr Sanjiv Agarwala predicts that the cancer biomarkers of the future may be “mobile biomarkers,” meaning measures of the tumor microenvironment or immune response that change with therapy and may be able to determine treatment efficacy.
Read More
How MSI and TMB Factor into Current Biomarker Testing Panels
By
Sanjiv S. Agarwala, MD
ASCO 2018 Insights
Videos
Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types.
Read More
Best Practices in How Oncologists and Pathologists Can Work Together to Optimize Biomarker Testing for Their Patients with Cancer
By
Sanjiv S. Agarwala, MD
ASCO 2018 Insights
Videos
Read More
Page 113 of 330
110
111
112
113
114
115
116
Top Trending Articles
1.
FDA Approves Acalabrutinib and Venetoclax Combination for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2.
FDA Launches Unified Adverse Event Monitoring System to Enhance Transparency and Efficiency
3.
Financial Toxicity in Cancer Care: Why the Conversation Must Start Before Treatment Begins
Jan Hailey, MHL, CMC, CMCO, CMIS, CMOM, CMCA-E/M
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma